Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications

Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin’s CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Bocco, Isabel H, Aleissa, Muneerah M, Zhou, Eric, Manne-Goehler, Jennifer, Koo, Sophia, Cheng, Matthew P, Marty, Francisco M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709895/
https://www.ncbi.nlm.nih.gov/pubmed/34988253
http://dx.doi.org/10.1093/ofid/ofab582
_version_ 1784623042771550208
author Gonzalez-Bocco, Isabel H
Aleissa, Muneerah M
Zhou, Eric
Manne-Goehler, Jennifer
Koo, Sophia
Cheng, Matthew P
Marty, Francisco M
author_facet Gonzalez-Bocco, Isabel H
Aleissa, Muneerah M
Zhou, Eric
Manne-Goehler, Jennifer
Koo, Sophia
Cheng, Matthew P
Marty, Francisco M
author_sort Gonzalez-Bocco, Isabel H
collection PubMed
description Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin’s CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-day mortality (0/13 vs 1/17; P = 1) in patients receiving clarithromycin vs azithromycin.
format Online
Article
Text
id pubmed-8709895
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87098952022-01-04 Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications Gonzalez-Bocco, Isabel H Aleissa, Muneerah M Zhou, Eric Manne-Goehler, Jennifer Koo, Sophia Cheng, Matthew P Marty, Francisco M Open Forum Infect Dis Brief Report Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin’s CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-day mortality (0/13 vs 1/17; P = 1) in patients receiving clarithromycin vs azithromycin. Oxford University Press 2021-12-18 /pmc/articles/PMC8709895/ /pubmed/34988253 http://dx.doi.org/10.1093/ofid/ofab582 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Gonzalez-Bocco, Isabel H
Aleissa, Muneerah M
Zhou, Eric
Manne-Goehler, Jennifer
Koo, Sophia
Cheng, Matthew P
Marty, Francisco M
Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
title Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
title_full Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
title_fullStr Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
title_full_unstemmed Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
title_short Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
title_sort clarithromycin–rifampin-based treatment for nontuberculous mycobacteria infections in immunocompromised patients who require concomitant cyp-metabolized medications
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709895/
https://www.ncbi.nlm.nih.gov/pubmed/34988253
http://dx.doi.org/10.1093/ofid/ofab582
work_keys_str_mv AT gonzalezboccoisabelh clarithromycinrifampinbasedtreatmentfornontuberculousmycobacteriainfectionsinimmunocompromisedpatientswhorequireconcomitantcypmetabolizedmedications
AT aleissamuneerahm clarithromycinrifampinbasedtreatmentfornontuberculousmycobacteriainfectionsinimmunocompromisedpatientswhorequireconcomitantcypmetabolizedmedications
AT zhoueric clarithromycinrifampinbasedtreatmentfornontuberculousmycobacteriainfectionsinimmunocompromisedpatientswhorequireconcomitantcypmetabolizedmedications
AT mannegoehlerjennifer clarithromycinrifampinbasedtreatmentfornontuberculousmycobacteriainfectionsinimmunocompromisedpatientswhorequireconcomitantcypmetabolizedmedications
AT koosophia clarithromycinrifampinbasedtreatmentfornontuberculousmycobacteriainfectionsinimmunocompromisedpatientswhorequireconcomitantcypmetabolizedmedications
AT chengmatthewp clarithromycinrifampinbasedtreatmentfornontuberculousmycobacteriainfectionsinimmunocompromisedpatientswhorequireconcomitantcypmetabolizedmedications
AT martyfranciscom clarithromycinrifampinbasedtreatmentfornontuberculousmycobacteriainfectionsinimmunocompromisedpatientswhorequireconcomitantcypmetabolizedmedications

Ejemplares similares